117 related articles for article (PubMed ID: 11823695)
1. Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study.
Plaxe SC; Blessing JA; Morgan MA; Carlson J;
Am J Clin Oncol; 2002 Feb; 25(1):45-7. PubMed ID: 11823695
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of pyrazoloacridine (PZA) in squamous carcinoma of the cervix--a Gynecologic Oncology Group Study.
Plaxe SC; Blessing JA; Lucci JA; Hurteau JA
Invest New Drugs; 2001; 19(1):77-80. PubMed ID: 11291835
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study.
Plaxe SC; Blessing JA; Bookman MA; Creasman WT
Gynecol Oncol; 2002 Jan; 84(1):32-5. PubMed ID: 11748972
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Plaxe SC; Blessing JA; Husseinzadeh N; Webster KD; Rader JS; Dunton CJ
Gynecol Oncol; 2002 Feb; 84(2):241-4. PubMed ID: 11812081
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial.
Galanis E; Buckner JC; Maurer MJ; Reid JM; Kuffel MJ; Ames MM; Scheithauer BW; Hammack JE; Pipoly G; Kuross SA
Invest New Drugs; 2005 Oct; 23(5):495-503. PubMed ID: 16133802
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
Plaxe SC; Blessing JA; Olt G; Husseinzadah N; Lentz SS; DeGeest K; Valea FA
Cancer Chemother Pharmacol; 2002 Aug; 50(2):151-4. PubMed ID: 12172981
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules.
Rowinsky EK; Noe DA; Grochow LB; Sartorious SE; Bowling MK; Chen TL; Lubejko BG; Kaufmann SH; Donehower RC
J Clin Oncol; 1995 Aug; 13(8):1975-84. PubMed ID: 7636538
[TBL] [Abstract][Full Text] [Related]
8. Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial.
Markman M; Blessing JA; DeGeest K; Morgan M; Look KY; Herzog TJ; Rose PG
Gynecol Oncol; 1999 Dec; 75(3):444-6. PubMed ID: 10600304
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors.
Vuky J; McCaffrey J; Ginsberg M; Mariani T; Bajorin DF; Bosl GJ; Motzer RJ
Invest New Drugs; 2000 Aug; 18(3):265-7. PubMed ID: 10958596
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma.
Zalupski MM; Shields AF; Philip PA; Kraut M; LoRusso P; Heilbrun LK; Vaitkevicius V
Invest New Drugs; 1998; 16(1):93-6. PubMed ID: 9740550
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma.
Zalupski MM; Philip PA; LoRusso P; Shields AF
Cancer Chemother Pharmacol; 1997; 40(3):225-7. PubMed ID: 9219505
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of pyrazoloacridine in advanced non-small cell carcinoma of the lung--a Kansas Cancer Institute and Thompson Cancer Survival Center Study.
Bastasch M; Panella TJ; Kretzschmer SL; Graham D; Mayo M; Williamson S
Invest New Drugs; 2002 Aug; 20(3):339-42. PubMed ID: 12201497
[TBL] [Abstract][Full Text] [Related]
13. A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancer.
Pelley R; Ganapathi R; Wood L; Rybicki L; McLain D; Budd GT; Peereboom D; Olencki T; Bukowski RM
Cancer Chemother Pharmacol; 2000; 46(3):251-4. PubMed ID: 11021744
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma.
Dodd PM; McCaffrey JA; Mazumdar M; Icasiano E; Higgins G; Herr H; Bajorin DF
Invest New Drugs; 2000 Aug; 18(3):247-51. PubMed ID: 10958593
[TBL] [Abstract][Full Text] [Related]
16. Pyrazoloacridine for the treatment of hormone-refractory prostate cancer.
Small EJ; Fippin LJ; Whisenant SP
Cancer Invest; 1998; 16(7):456-61. PubMed ID: 9774952
[TBL] [Abstract][Full Text] [Related]
17. A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer.
Adjei AA; Reid JM; Erlichman C; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Ruben S; Boemer SA; Atherton P; Ames MM; Kaufmann SH
Invest New Drugs; 2002 Aug; 20(3):297-304. PubMed ID: 12201492
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the gynecologic oncology group.
Manetta A; Blessing JA; Hurteau JA
Gynecol Oncol; 1998 Jan; 68(1):45-6. PubMed ID: 9454659
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).
LoRusso P; Foster BJ; Poplin E; McCormick J; Kraut M; Flaherty L; Heilbrun LK; Valdivieso M; Baker L
Clin Cancer Res; 1995 Dec; 1(12):1487-93. PubMed ID: 9815948
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma.
Berg WJ; McCaffrey J; Schwartz LH; Mariani T; Mazumdar M; Motzer RJ
Invest New Drugs; 1998-1999; 16(4):337-40. PubMed ID: 10426668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
